Full history for every metric is available with a Kvantra account
Freeline Therapeutics Holdings plc (FRLN)
Key financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | 0 | 0 | 0 | 0 | 0 | 1 |
| Operating profit | $m | -98 | -68 | |||||
| Net profit | $m | - | -33 | -54 | -96 | -140 | -89 | -50 |
| EPS reported | $ | -22.52 | -11.47 | |||||
| Operating cashflow per share | $ | -19.80 | -19.80 | |||||
| Capex per share | $ | 1.78 | 1.78 | |||||
| FCF per share | $ | -21.57 | -21.57 | |||||
| Free cash flow | $m | -85 | -69 | |||||
| Net debt | $m | -41 | -29 | |||||
| Book value equity | $m | 52 | 30 | |||||
| Book value per share | $ | 13.26 | 6.89 | |||||
| Number of shares | m | 3.95 | 4.36 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.54 | 0.94 | |||||
| P/S LTM | x | 0.00 | 45.47 | |||||
| P/FCF LTM | x | -0.33 | -0.41 | |||||
| EV/EBITDA LTM | x | 0.14 | 0.01 | |||||
| EV/Sales LTM | x | 0.00 | -1.88 | |||||
| Earnings Yield LTM | % | -315.80% | -346.94% | |||||
| FCF Yield | % | -302.54% | -243.23% | |||||
| Quality | ||||||||
| ROE | % | -169.75% | -102.94% | |||||
| ROIC | % | -168.75% | -168.75% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -14.39 | -17.25 | |||||
| Net Debt/EBITDA | x | 0.43 | 0.43 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -146.79% | -104.13% | |||||
| Net debt/Equity | x | -0.79 | -0.98 | |||||
| Gross debt/equity | x | 0.11 | 0.13 | |||||
Company overview
Freeline Therapeutics Holdings plc is a biopharmaceutical company, currently in its clinical development phase, focused on creating groundbreaking gene therapies. These innovative treatments leverage adeno-associated virus (AAV) vector technology to tackle inherited, systemic, and severely debilitating genetic conditions. The company's leading therapeutic candidate, verbrinacogene setparvovec (FLT180a), is presently undergoing Phase 1/2 clinical trials for the management of hemophilia B in adult males. Furthermore, Freeline's pipeline features FLT190, which is also in Phase 1/2 clinical evaluation for treating Fabry disease, and FLT201, a gene therapy designed to target the liver for type 1 Gaucher disease, likewise progressing through Phase 1/2 trials. Beyond these specific programs, the company is actively pursuing research initiatives across a range of other systemic gene therapy indications. Freeline was established in 2015 and operates from its headquarters in Stevenage, United Kingdom.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Freeline Therapeutics Holdings plc (FRLN)
Freeline Therapeutics Holdings plc is a biopharmaceutical company, currently in its clinical development phase, focused on creating groundbreaking gene therapies. These innovative treatments leverage adeno-associated virus (AAV) vector technology to tackle inherited, systemic, and severely debilitating genetic conditions. The company's leading therapeutic candidate, verbrinacogene setparvovec (FLT180a), is presently undergoing Phase 1/2 clinical trials for the management of hemophilia B in adult males. Furthermore, Freeline's pipeline features FLT190, which is also in Phase 1/2 clinical evaluation for treating Fabry disease, and FLT201, a gene therapy designed to target the liver for type 1 Gaucher disease, likewise progressing through Phase 1/2 trials. Beyond these specific programs, the company is actively pursuing research initiatives across a range of other systemic gene therapy indications. Freeline was established in 2015 and operates from its headquarters in Stevenage, United Kingdom.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free